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Aims Chronic ischaemic cardiovascular disease (CICD) is a major cause of mortality and morbidity worldwide. The primary
objective of the CICD-Pilot registry was to describe the clinical characteristics and management modalities across
Europe in a broad spectrum of patients with CICD.
Methods
and results
The CICD-Pilot registry is an international prospective observational longitudinal registry, conducted in 100 centres
from 10 countries selected to reflect the diversity of health systems and care attitudes across Europe. From April
2013 to December 2014, 2420 consecutive CICD patients with non-ST-elevation acute coronary syndrome
(n ¼ 755) and chronic stable coronary artery disease (n ¼ 1464), of whom 933 (63.7%) were planned for elective cor-
onary intervention, or with peripheral artery disease (PAD) (n ¼ 201), were enrolled (30.5% female patients). Mean age
was 66.6+10.9 years. The following risk factors were reported: smoking 54.6%, diabetes mellitus 29.2%, hypertension
82.6%, and hypercholesterolaemia 74.1%. Assessment of cardiac function was made in 69.5% and an exercise stress test
in 21.2% during/within 1 year preceding admission. New stress imaging modalities were applied in a minority of patients.
A marked increase was observed at discharge in the rate of prescription of angiotensin-converting enzyme-inhibitors/
angiotensin receptor blockers (82.8%), beta-blockers (80.2%), statins (92.7%), aspirin (90.3%), and clopidogrel (66.8%).
Marked differences in clinical profile and treatment modalities were observed across the four cohorts.
Conclusion The CICD-Pilot registry suggests that implementation of guideline-recommended therapies has improved since the
previous surveys but that important heterogeneity exists in the clinical profile and treatment modalities in the different
cohorts of patients enrolled with a broad spectrum of CICDs.
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Introduction
Coronary artery disease (CAD) remains the first cause of death
worldwide and is a major burden for healthcare systems.1,2 It is
expected to remain the leading cause of mortality and morbidity
in 2020 despite considerable progress in diagnosis and treatment.3
The landscape of CAD diagnosis and management has consider-
ably changed with new stress imaging modalities for the diagnosis,
improved prevention measures, and more efficient revascularization
therapies, whereas ageing populations are more prone to develop
the disease and are therefore at high risk of myocardial infarction,
sudden cardiac death, or heart failure. Scientific societies such as
the European Society of Cardiology (ESC), the American College
of Cardiology, and the American Heart Association have recently
updated their recommendations accordingly.4,5
In addition, important geographic variations in presentation, risk
factors, and diagnostic modalities have been identified in a previous
European survey on patients with stable angina presenting to Euro-
pean cardiologists. However, this survey did not include any follow-
up and was therefore unable to assess whether clinical outcomes
are influenced by geographic variations or not.6
In this context, it is important to reassess in a contemporary en-
vironment the clinical profile and the diagnostic and treatment strat-
egies of a broad spectrum of patients with chronic ischaemic
cardiovascular disease (CICD).
As atherosclerosis is a systemic disease, it is also important that
physicians appreciate the importance of detecting atherosclerosis
in other vascular beds than the coronary circulation and, as shown
in the Reduction of Atherosclerosis for Continued Health (REACH)
Registry, a substantial percentage of patients with chronic CAD have
indeed frequently cerebrovascular disease, low extremity artery dis-
ease, or both.7
The purpose of the CICD registry is therefore to characterize
CICD including patients with peripheral artery disease (PAD) in
terms of demographic characteristics, clinical profiles management,
and outcomes and to identify inter-regional differences and poten-
tial gaps between actual treatment and evidence-based recommen-
dations in participating countries.
The CICD-Pilot phase is aimed at validating the structure, per-
formance, feasibility, and quality of the data set, with the intention
of extending the survey to other participating ESC countries into
a long-term registry.
Baseline characteristics and treatment modalities of patients re-
cruited in the 10 participating countries are described in this article.
Methods
Study design
The CICD-Pilot survey is an international prospective observational
longitudinal registry in CAD and/or PAD patients with 3-year follow-up.
The study has been approved by local Institutional Review Boards,
and all patients gave informed consent in accordance with national
and local regulations. Patients were recruited in 100 centres from 10
countries selected on the basis of geographic distribution:
† two Western European countries (France and Germany, 20 centres,
n ¼ 405 patients);
† two Northern (Latvia and Lithuania, six centres, n ¼ 404 patients);
† three Eastern (Poland, Romania, and Russian Federation, 45 centres,
n ¼ 1025 patients);
† three Southern (Greece, Italy, and Portugal, 29 centres, n ¼ 586
patients).
The National Cardiac Societies of each participating country agreed to
participate in the programme and were asked to select centres able to
recruit patients for four different cohorts:
† Cohort 1: consecutive patients with chronic CAD and non-ST eleva-
tion acute coronary syndrome undergoing a percutaneous coronary
intervention (PCI) within 72 h from symptom onset, enrolled in the
catheterization laboratory (ACS PCI group);
† Cohort 2: consecutive patients with chronic stable CAD undergoing
elective coronary intervention enrolled in the catheterization labora-
tory (elective PCI group);
† Cohort 3: stable CAD patients enrolled in general hospitals and clinics
without interventional and cardiovascular surgery facilities (stable
CAD group);
† Cohort 4: consecutive patients with peripheral artery interventions
(PAD group).
The theoretical number of participating centres for each country was
decided according to the population of each country: one centre with
interventional facilities per two million inhabitants for cohorts 1 and
2, with a maximum of 30 centres per country and about 15–30 centres
per country for cohort 3. Centres performing more than 30 procedures
per year were selected to recruit in cohort 4. However, the actual num-
ber of centres was lower than expected, and overall one hundred cen-
tres took part in the survey. Each centre was asked to enrol at least 20
consecutive patients.
Local monitoring visits were performed to check the quality of the
collected data and the consecutiveness of enrolment in a sample of cen-
tres chosen on a monitoring risk-based strategy.
The survey was conducted by an independent executive committee
(Appendix), responsible for the formulation and implementation of the
study protocol.
A steering committee, composed of two co-chairpersons of the
executive committee and of each national coordinator of the study,
was created in order to ensure national feedback on the protocol and
proper implementation of the survey at the national level.
The EURObservational Research Programme (EORP) department of
the ESC was appointed to (i) coordinate the project and the operations
of the CICD-Pilot; (ii) provide support to the committees, national co-
ordinators, and participating centres; and (iii) ensure quality control of
data and study procedure.
This survey was approved by each local or national Institutional Re-
view Board according to the national regulations of each participating
country. No data were collected before detailed information was pro-
vided to the patient, and a signed informed consent was obtained.
The database was set up at the European Heart House, according to
the requirements defined by the Executive Committee, and the statistical
analyses were performed by the EORP Department.
Statistical analysis
Univariate analysis was applied to both continuous and categorical vari-
ables. Continuous variables were reported as mean+ SD and/or as me-
dian and interquartile range (IQR). Among-group comparisons were
made using a non-parametric test (Kruskal–Wallis test). Categorical
variables were reported as percentages. Among-group comparisons
were made using a x2 test or a Fisher’s exact test if any expected cell
count was less than five.
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A two-sided P-value less than 0.05 was considered statistically signifi-
cant. All analyses were performed using SAS statistical software version
9.4 (SAS Institute, Inc., Cary, NC, USA).
Results
From April 2013 to December 2014, 2420 patients were enrolled: 755
in ACS PCI, 933 in elective PCI, 531 in stable CAD, and 201 in PAD.
Ten patients did not provide consent and are therefore not
included in the database.
Clinical profile of the patients
The baseline characteristics of the overall population and of the
four individual cohorts are provided in Table 1.
Mean age was 66.6 years and was slightly higher in patients en-
rolled in ACS PCI or elective PCI cohorts than in stable CAD and
PAD cohorts. Female patients accounted for 30.5% of the patients.
Diabetes mellitus was reported in 29.2% of the patients and was
more prevalent (49.3%) in cohort 4. Smoking (current/former)
was observed in 54.6% of the patients and was highly prevalent in
cohorts 1 (60.4%) and 4 (64.7%).
A history of hypertension was reported in 82.6% of the cases and
of hypercholesterolaemia in 74.1%. About 16.6% of the female pa-
tients and 51.4% of the male patients had an age of ,55 (females)
and ,60 years (males) at the time of first cardiovascular disease
manifestation. Mean systolic blood pressure was higher in the
PAD patients than in those from the other three cohorts.
A history of previous ST elevation acute coronary syndrome
(STEMI) and non-ST elevation acute coronary syndrome (NSTEMI)
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Table 1 Demographics and other baseline characteristics by cohort
Cohort, all Cohort 1,
ACS PCI
Cohort 2,
elective PCI
Cohort 3,
stable CAD
Cohort 4, PAD P-value
No. of patients 2420 755 933 531 201
Age at inclusion
N 2420 755 933 531 201 0.0087
Mean+ SD 66.6+10.9 66.0+11.7 66.2+10.1 67.3+11.2 68.6+10.6
Median (IQR) 67.0 (59.0–75.0) 66.0 (58.0–75.0) 66.0 (59.0–74.0) 67.0 (59.0–76.0) 70.0 (60.0–76.0)
Female gender 739/2420 (30.5%) 242/755 (32.1%) 266/933 (28.5%) 181/531 (34.1%) 50/201 (24.9%) 0.0318
SBP (mmHg)
N 2414 755 933 528 198 0.0002
Mean+ SD 136.5+20.2 137.7+22.0 135.4+17.7 134.7+21.0 141.3+21.3
Median (IQR) 134.0 (120.0–150.0) 136.0 (120.0–150.0) 132.0 (120.0–147.0) 130.0 (120.0–148.0) 140.0 (130.0–155.0)
HR (b.p.m.)
N 2419 755 932 531 201 ,0.0001
Mean+ SD 70.4+13.1 73.3+13.7 67.6+10.6 71.4+15.3 70.1+12.0
Median (IQR) 70.0 (61.0–77.0) 71.0 (64.0–80.0) 67.0 (60.0–73.0) 70.0 (62.0–78.0) 70.0 (60.0–76.0)
Diabetes mellitus 706/2420 (29.2%) 215/755 (28.5%) 254/933 (27.2%) 138/531 (26.0%) 99/201 (49.3%) ,0.0001
Smoking status 1321/2420 (54.6%) 456/755 (60.4%) 465/933 (49.8%) 270/531 (50.8%) 130/201 (64.7%) ,0.0001
Hypertension 1998/2420 (82.6%) 605/755 (80.1%) 785/933 (84.1%) 434/531 (81.7%) 174/201 (86.6%) 0.0659
Hypercholesterolaemia 1793/2419 (74.1%) 522/755 (69.1%) 735/932 (78.9%) 383/531 (72.1%) 153/201 (76.1%) ,0.0001
Previous NSTE ACS 488/2420 (20.2%) 167/755 (22.1%) 166/933 (17.8%) 142/531 (26.7%) 13/201 (6.5%) ,0.0001
Previous STEMI ACS 594/2420 (24.5%) 156/755 (20.7%) 291/933 (31.2%) 125/531 (23.5%) 22/201 (10.9%) ,0.0001
Previous peripheral
revascularization
142/2420 (5.9%) 28/755 (3.7%) 30/933 (3.2%) 17/531 (3.2%) 67/201 (33.3%) ,0.0001
Chronic kidney disease 275/2397 (11.5%) 85/746 (11.4%) 86/928 (9.3%) 71/523 (13.6%) 33/200 (16.5%) 0.0085
Previous stable CAD 1633/2420 (67.5%) 335/755 (44.4%) 794/933 (85.1%) 427/531 (80.4%) 77/201 (38.3%) ,0.0001
Previous
revascularization
(PCI/CABG)
998/1633 (61.1%) 227/335 (67.8%) 455/794 (57.3%) 257/427 (60.2%) 59/77 (76.6%) 0.0003
Previous
cerebrovascular
disease
396/2420 (16.4%) 83/755 (11.0%) 133/933 (14.3%) 91/531 (17.1%) 89/201 (44.3%) ,0.0001
Chronic obstructive
pulmonary disease
165/2370 (7.0%) 52/738 (7.0%) 48/912 (5.3%) 41/522 (7.9%) 24/198 (12.1%) 0.0050
SD, standard deviation; IQR, interquartile range; SBP, systolic blood pressure; HR, heart rate; STE ACS, ST elevation acute coronary syndrome; NSTE ACS, non-ST elevation acute
coronary syndrome; CAD, coronary artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft.
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was reported in 24.5 and 20.2% of the cases, respectively, but a his-
tory of STEMI and NSTEMI was less common in the PAD cohort
(10.9 and 6.5%, respectively).
About 67.5% of the patients had a previous history of stable CAD,
and most of these patients were in Canadian Cardiovascular Society,
Class I or II (71.9%). A history of previous stable CAD was less fre-
quent in the ACS PCI and PAD cohorts. About 46.4% of the patients
had undergone a previous PCI and 14.7% a previous coronary artery
bypass surgery, and the proportion of patients with a previous per-
ipheral revascularization was much higher in the PAD patients
(33.3%) than in the other cohorts (3.2–3.7%).
Approximately 16.4% had experienced a previous cerebrovascu-
lar disease and 15.1% had a history of atrial fibrillation. Chronic ob-
structive pulmonary disease was reported in 7.0% of the patients
and malignancy in 6.6%. About 54.8% of the patients had at least
three of the following major cardiovascular risk factors: diabetes
mellitus, hypertension, hypercholesterolaemia, smoking, or early
manifestation of cardiovascular disease, and the proportion was
particularly high (70.6%) in PAD patients.
Previous cerebrovascular disease was reported in 44.3% of the
PAD patients, compared with 11–17.1% in the other cohorts. Simi-
larly, a history of chronic kidney disease was more common in the
PAD cohort (16.5 vs. 9.3–13.6%).
Investigations
Non-invasive investigations
Baseline investigations performed during admission/consultation or
during the previous year are given in Table 2. Mean serum creatinine
was slightly increased in this elderly population as was fasting
glucose. Fasting glucose was higher in the PAD and ACS PCI cohorts
than in the other two cohorts.
Total cholesterol was 169.9+49.3 mg/dL and low-density lipo-
protein (LDL) cholesterol was 101.7+42.7 mg/dL. LDL cholesterol
was higher in the ACS PCI patients than that in the other patients.
An echocardiogram was performed in 69.5% of the patients
with important variations between cohorts (84.0% in cohort 1 vs.
60.4% in cohort 2, 77.4% in cohort 3, and 35.8% in cohort 4).
When measured, mean ejection fraction was in the normal range
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Table 2 Investigations during admission/consultation or within 1 year by cohort
Cohort, all Cohort 1, ACS PCI Cohort 2,
elective PCI
Cohort 3,
stable CAD
Cohort 4, PAD P-value
No. of patients 2420 755 933 531 201
S-creatinine (mg/dL)
N 2341 732 892 517 200 0.0296
Mean+ SD 1.15+2.68 1.06+0.72 1.05+0.78 1.43+5.51 1.16+0.91
Median (IQR) 0.94 (0.80–1.15) 0.93 (0.78–1.16) 0.94 (0.80–1.10) 0.97 (0.83–1.20) 0.97 (0.80–1.15)
Fasting glucose (mg/dL)
N 2149 701 773 476 199 ,0.0001
Mean+ SD 116.20+44.02 124.02+47.46 109.90+38.99 110.10+37.85 127.73+55.68
Median (IQR) 103.00 (91.00–125.33) 110.00 (95.16–137.00) 99.00 (89.00–117.00) 100.00 (90.00–114.83) 109.67 (94.00–145.00)
C-reactive protein (mg/dL)
N 1089 446 307 242 94 0.0185
Mean+ SD 8.54+25.69 10.98+32.39 6.24+23.82 7.36+15.27 7.48+13.49
Median (IQR) 2.40 (1.00–6.40) 3.05 (1.00–7.70) 2.20 (1.00–5.00) 1.70 (0.80–5.60) 2.84 (1.00–7.00)
LDL (mg/dL)
N 1946 639 686 452 169 ,0.0001
Mean+ SD 101.7+42.7 110.4+44.8 100.7+43.1 94.9+37.8 91.6+38.7
Median (IQR) 95.7 (71.0–125.0) 105.0 (78.6–136.0) 95.4 (72.0–124.0) 87.0 (68.0–116.2) 83.0 (63.0–114.0)
Total cholesterol (mg/dL)
N 2067 665 757 469 176 ,0.0001
Mean+ SD 169.9+49.3 179.0+50.0 167.0+50.1 165.9+46.0 159.2+46.8
Median (IQR) 163.0 (134.0–199.7) 173.3 (144.0–211.0) 160.0 (133.0–194.0) 161.0 (133.0–191.0) 148.0 (124.8–189.0)
Atrial fibrillation 180/2371 (7.6%) 42/747 (5.6%) 46/904 (5.1%) 79/523 (15.1%) 13/197 (6.6%) ,0.0001
LV ejection fraction (%)
N 1608 622 538 382 66 ,0.0001
Mean+ SD 52.5+11.3 50.8+10.6 52.7+11.1 54.3+12.3 54.6+11.6
Median (IQR) 55.0 (46.0–60.0) 51.0 (45.0–60.0) 55.0 (48.0–60.0) 57.0 (50.0–62.0) 60.0 (50.0–60.0)
SD, standard deviation; IQR, interquartile range; LDL, low-density lipoprotein; LV, left ventricle.
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(52.5+ 11.3%), whereas left ventricular hypertrophy was reported
in nearly half of the patients.
A Holter monitoring was performed in 14.5% of the patients,
mainly in cohorts 1 and 3 (13.7 and 28.0%, respectively).
An exercise test was performed during/within 1 year preceding
admission/consultation in 21.2% of the cases, whereas stress imaging
techniques were uncommon [myocardial scintigraphy 4.0%, cardiac
computed tomography (CT) 2.0%, and cardiac magnetic resonance
imaging (MRI) 0.9%]. An implantable cardioverter defibrillator had
been implanted in only 2.2% of the patients before admission.
Invasive investigations
As expected, time to coronary angiography differed substantially
between ACS PCI and elective PCI cohorts; 80.5% of the patients
with elective angiography had their procedure done at least 1 month
after the onset of symptoms, whereas 70% of the patients with
NSTEMI were referred to the catheter laboratory within 72 h.
About 15.6% of the patients enrolled in cohorts 1 and 2 had left
main disease and 33.5% a single vessel (.50%) disease, whereas
27.9% had lesions on two arteries and 22.9% on three arteries.
Fractional flow reserve (3.7%), thrombus aspiration (1.5%), and
optical CT (0.8%) concerned only a limited number of patients.
Drug treatments
Table 3 provides the drug treatments before admission/consultation
and Table 4 treatments at discharge. Before admission, angiotensin-
converting enzyme-inhibitors (ACE-I) or angiotensin receptor block-
ers (ARBs) were prescribed in 67.8%, beta-blockers in 63.8%, diuret-
ic agents in 30.7%, dihydropiridine (DHP) calcium channel blockers
in 19.6%, nitrates in 11.1%, amiodarone in 2.8%, ivabradine in 3.1%,
ranolazine in 1.4%, and trimetazidine in 3.8%.
Statins were prescribed in 67.5% of the patients. Atorvastatin ac-
counted for 64.2% of those prescriptions and simvastatin 19.7%
(data not shown).
Insulin therapy and oral antidiabetic agents were prescribed in 9.4
and 19.9% of the patients, respectively.
Vitamin K antagonists were prescribed in 7.4%, new oral anticoa-
gulants in 1.8%, aspirin in 68.2%, clopidogrel in 29.6%, and other anti-
platelet agents in 3.4% of the patients.
Drug treatment before admission differed between groups:
patients with PAD or cerebrovascular disease were less prone to re-
ceive ACE-inhibitors or beta-blockers and more likely to be treated
with dihydropyridine calcium channel blockers, statins, glucose-
lowering medications, aspirin, and clopidogrel.
ACS PCI patients were less likely to be treated with ACE-Is, min-
eralocorticoid receptor antagonists (MRAs), diuretics, dihydropyridine
calcium channel blockers, and statins before admission than the elect-
ive PCI and the stable CAD patients.
At discharge, the prescription rate of ACE-inhibitors/ARBs
(82.9%), beta-blockers (80.2%), and statins (92.7%) as well as aspirin
(90.3%) and clopidogrel (66.8%), or other antiplatelet agents
(12.3%) markedly increased. Yet, the drug regimen at discharge
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Table 3 Drug treatment before hospital admission/consultation
Cohort, all Cohort 1,
ACS PCI
Cohort 2,
elective PCI
Cohort 3, stable
CAD
Cohort 4,
PAD
P-value
No. of patients 2420 755 933 531 201
ACE-Is 1163/2312 (50.3%) 313/711 (44.0%) 518/899 (57.6%) 257/515 (49.9%) 75/187 (40.1%) ,0.0001
ARBs 424/2333 (18.2%) 98/724 (13.5%) 188/903 (20.8%) 83/519 (16.0%) 55/187 (29.4%) ,0.0001
ACE-I/ARBs 1568/2311 (67.8%) 408/711 (57.4%) 696/898 (77.5%) 336/515 (65.2%) 128/187 (68.4%) ,0.0001
Beta-blockers 1489/2333 (63.8%) 392/722 (54.3%) 662/907 (73.0%) 347/516 (67.2%) 88/188 (46.8%) ,0.0001
MRAs 177/2341 (7.6%) 36/728 (4.9%) 70/909 (7.7%) 58/517 (11.2%) 13/187 (7.0%) 0.0007
Diuretics 717/2334 (30.7%) 171/725 (23.6%) 280/910 (30.8%) 183/513 (35.7%) 83/186 (44.6%) ,0.0001
DHP calcium channel blockers 462/2355 (19.6%) 114/735 (15.5%) 199/915 (21.7%) 92/518 (17.8%) 57/187 (30.5%) ,0.0001
Non-DHP calcium channel blockers 47/2370 (2.0%) 15/737 (2.0%) 17/923 (1.8%) 11/522 (2.1%) 4/188 (2.1%) 0.9828
Amiodarone 66/2366 (2.8%) 16/737 (2.2%) 19/922 (2.1%) 19/518 (3.7%) 12/189 (6.3%) 0.0043
Statins 1551/2298 (67.5%) 347/706 (49.2%) 716/900 (79.6%) 342/508 (67.3%) 146/184 (79.3%) ,0.0001
Nitrates 262/2357 (11.1%) 75/736 (10.2%) 133/914 (14.6%) 43/519 (8.3%) 11/188 (5.9%) 0.0001
Ivabradine 73/2365 (3.1%) 14/737 (1.9%) 40/918 (4.4%) 19/522 (3.6%) – 0.0019
Ranolazine 32/2366 (1.4%) 7/738 (0.9%) 17/921 (1.8%) 6/519 (1.2%) 2/188 (1.1%) 0.4153
Insulin 215/2296 (9.4%) 73/694 (10.5%) 55/893 (6.2%) 46/523 (8.8%) 41/186 (22.0%) ,0.0001
Oral antidiabetics 472/2377 (19.9%) 128/739 (17.3%) 198/924 (21.4%) 98/524 (18.7%) 48/190 (25.3%) 0.0393
Oral anticoagulant drugs 215/2352 (9.1%) 39/729 (5.3%) 77/914 (8.4%) 72/521 (13.8%) 27/188 (14.4%) ,0.0001
ASA 1594/2337 (68.2%) 376/721 (52.1%) 727/913 (79.6%) 340/517 (65.8%) 151/186 (81.2%) ,0.0001
Clopidogrel 697/2352 (29.6%) 161/729 (22.1%) 382/911 (41.9%) 81/523 (15.5%) 73/189 (38.6%) ,0.0001
Other antiplatelet agents excluding
clopidogrel
79/2352 (3.4%) 22/729 (3.0%) 39/911 (4.3%) 13/523 (2.5%) 5/189 (2.6%) 0.2434
x2 or Fisher’s exact test [a] is used for binary variables.
ACE-I, angiotensin-converting enzyme inhibitor; ARBs, angiotensin II receptor blockers; MRAs, mineralocorticoid receptor antagonists; DHP, dihydropyridine; ASA, acetylsalicylic acid.
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differed between the four cohorts, particularly between PAD pa-
tients and those included in the other three cohorts.
This was also true for combination therapy: 71.5% of the patients
received a combination of ACE-I/ARB, aspirin, and statins at dis-
charge when compared with only 44.5% before admission.
The rate of prescription of recent antianginal agents was low,
4.1% for ivabradine and 1.4% for ranolazine, as was the utilization
of new antiplatelet agents except in cohort 1 (26.4%).
Table 5 summarizes key demographic data and management
modalities in the current CICD-Pilot registry and in the previous
Euro Heart Survey (EHS) on stable angina published in 2005.
Only three patients died in hospital: one in cohort 1, one in
cohort 3, and one in cohort 4.
Discussion
The CICD-Pilot survey shows substantial trends in the changing
profile of patients with CICD in Europe as well as management mo-
dalities. It also shows important differences across the four cohorts
of patients.
Clinical profile
Compared with a previous EHS conducted in Europe and including
3779 patients with stable angina pectoris, patients enrolled in the
CICD-Pilot survey were older and had more frequently a history
of diabetes, dyslipidaemia, hypertension, cerebrovascular disease,
and malignancy, whereas the rate of chronic pulmonary disease
was similar.6 Also the proportion of patients with severe angina
defined by a CCS class III was higher in the cohort of patients
with planned PCI than in the previous survey. These findings suggest
that patients with CICD are more complex and have more
comorbidities than 10 years ago.
The plasma level of LDL cholesterol was lower in our registry
than that in the previous EHS. This likely reflects a higher prescrip-
tion rate of statins (67 vs. 48%) and other lipid-lowering agents and
suggests that guideline recommendations for the management of
hypercholesterolaemia are better implemented. The mean LDL
plasma level reported here remains, however, higher than the cur-
rent recommended target in patients with established cardiovascu-
lar disease (≤70 mg/dL).4
The clinical profile of the patients enrolled in the CICD registry is
closer to that of patients enrolled in the CLARIFY registry, a large
contemporary international registry of patients with stable CAD
with/without angina and with/without documented ischaemia en-
rolled in many countries across the world.8
We also observed important differences in the clinical profile of
the four cohorts of patients. Specifically, PAD patients were older,
had a higher systolic blood pressure, were more likely to be males,
smokers, or to be affected by comorbidities such as diabetes melli-
tus, hypertension, chronic kidney disease, cerebrovascular disease,
or chronic obstructive pulmonary disease than the other patients.
This finding illustrates the broad spectrum of clinical presentation
of patients affected by atherosclerosis and confirms data from large
international registries.7
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Table 4 Drug treatment at discharge/after consultation
Cohort, all Cohort 1,
ACS PCI
Cohort 2,
elective PCI
Cohort 3,
stable CAD
Cohort 4,
PAD
P-value
No. of patients 2420 755 933 531 201
ACE-I 1573/2417 (65.1%) 565/754 (74.9%) 608/933 (65.2%) 315/529 (59.5%) 85/201 (42.3%) ,0.0001
ARBs 447/2417 (18.5%) 86/754 (11.4%) 193/933 (20.7%) 106/529 (20.0%) 62/201 (30.8%) ,0.0001
ACE-Is/ARBs 2002/2417 (82.8%) 648/754 (85.9%) 794/933 (85.1%) 415/529 (78.4%) 145/201 (72.1%) ,0.0001
Beta-blockers 1939/2417 (80.2%) 639/754 (84.7%) 758/933 (81.2%) 440/529 (83.2%) 102/201 (50.7%) ,0.0001
MRAs 276/2417 (11.4%) 99/754 (13.1%) 71/933 (7.6%) 91/529 (17.2%) 15/201 (7.5%) ,0.0001
Diuretics 876/2417 (36.2%) 222/754 (29.4%) 324/933 (34.7%) 237/529 (44.8%) 93/201 (46.3%) ,0.0001
DHP calcium channel blockers 540/2417 (22.3%) 140/754 (18.6%) 223/933 (23.9%) 113/529 (21.4%) 64/201 (31.8%) 0.0004
Non-DHP calcium channel blockers 50/2417 (2.1%) 16/754 (2.1%) 16/933 (1.7%) 13/529 (2.5%) 5/201 (2.5%) 0.7636
Amiodarone 82/2416 (3.4%) 19/753 (2.5%) 25/933 (2.7%) 27/529 (5.1%) 11/201 (5.5%) 0.0144
Statins 2241/2417 (92.7%) 717/754 (95.1%) 891/933 (95.5%) 453/529 (85.6%) 180/201 (89.6%) ,0.0001
Nitrates 293/2417 (12.1%) 109/754 (14.5%) 94/933 (10.1%) 75/529 (14.2%) 15/201 (7.5%) 0.0033
Ivabradine 99/2417 (4.1%) 23/754 (3.1%) 52/933 (5.6%) 22/529 (4.2%) 2/201 (1.0%) 0.0067
Ranolazine 33/2417 (1.4%) 7/754 (0.9%) 16/933 (1.7%) 8/529 (1.5%) 2/201 (1.0%) 0.5310
Insulin 238/2337 (10.2%) 84/711 (11.8%) 59/899 (6.6%) 47/526 (8.9%) 48/201 (23.9%) ,0.0001
Oral antidiabetics 485/2417 (20.1%) 139/754 (18.4%) 197/933 (21.1%) 96/529 (18.1%) 53/201 (26.4%) 0.0444
Oral anticoagulant drugs 275/2415 (11.4%) 63/754 (8.4%) 87/932 (9.3%) 94/528 (17.8%) 31/201 (15.4%) ,0.0001
ASA 2183/2417 (90.3%) 700/754 (92.8%) 887/933 (95.1%) 416/529 (78.6%) 180/201 (89.6%) ,0.0001
Clopidogrel 1615/2417 (66.8%) 518/754 (68.7%) 795/933 (85.2%) 126/529 (23.8%) 176/201 (87.6%) ,0.0001
Other antiplatelet agents excluding
clopidogrel
298/2417 (12.3%) 199/754 (26.4%) 75/933 (8.0%) 20/529 (3.8%) 4/201 (2.0%) ,0.0001
x2 or Fisher’s exact test [a] is used for binary variables.
ACE-I, angiotensin-converting enzyme inhibitor; ARBs, angiotensin II receptor blockers; MRAs, mineralocorticoid receptor antagonists; DHP, dihydropyridine; ASA, acetylsalicylic acid.
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Investigations
Evaluation of cardiac function by echocardiography is recom-
mended by the ESC guidelines in all patients with stable CAD in
order to identify regional wall motion abnormalities, measure ejec-
tion fraction, and evaluate diastolic function.3 In the CICD-Pilot
registry, it was measured only in 70% of the patients overall and
only in one-third of patients with PAD.
Assessment of myocardial ischaemia during hospitalization/
consultation or within 1 year was made in only 50% of the patients
with stable CAD and 37% of those with planned elective angioplasty,
a much smaller proportion than that observed in the previous
European survey.
The use of new imaging modalities including cardiac CT, myocar-
dial scintigraphy, or cardiac magnetic resonance was marginal, and
most of the stress test procedures used conventional exercise
test. The low rate of use of modern imaging modalities may in
part be explained by geographic variations and related differences
in access to these techniques as .40% of our patients were
recruited in Central/Eastern European countries. We indeed
found that there was a statistically significant lower use of stress
imaging modalities (myocardial scintigraphy, P, 0.001 and MRI,
P, 0.0022) and of CT scan, P, 0.001, in Eastern countries,
compared with the other three European regions.
Nevertheless, these findings show that implementation of the re-
cent ESC guidelines in which imaging stress testing plays a central
role remains suboptimal and that there is room for improvement.
Drug treatments
Important differences exist between this pilot registry and the pre-
vious EHS regarding antianginal therapies at discharge: the use of
beta-blockers was higher in the current survey, whereas nitrates
were prescribed nearly five times less and calcium antagonists
slightly less than in the EHS population.
Similarly, the use of ACE-inhibitors and aspirin was markedly
higher in the CICD-Pilot survey. As the use of other antiplatelet
agents was not recorded in EHS, no comparison is possible with
our study regarding this point.
Differences inherent to the constitution of cohorts (i.e. NSTE-
MI and PAD patients) may account for some of the variations ob-
served in drug therapy. We indeed observed that PAD patients
were less likely to be treated by ACE-Is, beta-blockers, MRAs,
or antianginal drugs and more likely to be on diuretic agents, dihy-
dropyridine calcium channel blockers, insulin, or oral antidiabetic
agents than the patients enrolled in the other cohorts. In contrast,
use of aspirin at discharge was high (except in stable CAD pa-
tients) as was the use of clopidogrel or other antiplatelet agents.
Overall, our findings suggest that guideline-recommended therap-
ies are better implemented in the current registry than they were
in 2005.
Another important observation is the fact that both antianginal
drugs and drugs recommended for secondary prevention were sub-
stantially more prescribed at discharge than before admission or
consultation, suggesting that physicians taking care of the patients
enrolled in the CICD-Pilot registry tried to implement guideline-
recommended therapies.4
Overall, the rate of prescription of therapies used in secondary
prevention is similar to that observed in the most recent EuroAspire
IV studies.9,10 In these large European registries enrolling patients
from 78 centres in 24 countries with established CAD, a high use
of these therapies was reported, but large variations in secondary
prevention practice were noticed among centres.
There are, however, important differences in the rate of
prescription of life-saving drugs or antianginal medications
between the CICD-Pilot survey and the CLARIFY registry: the
rate of prescription of ACE-Is/ARBs, beta-blockers, aspirin, and
particularly of thienopyridines at discharge is higher in the CICD-
Pilot registry. This is partly due to the fact that our study enrolled
patients with NSTEMI, but geographic variations between differ-
ent regions of the world may also be responsible for these
differences.
This registry has important limitations.
Although the setting of recruiting centres was clearly defined and
uniform across different countries (catheter laboratory for cohorts
1, 2, and 4 and clinics in hospital without cardiovascular interven-
tional facilities for cohort 3), selection of centres was made on a
voluntary basis, and we therefore cannot exclude a centre bias
regarding the clinical profile, the investigations, and the treatment
of patients enrolled.
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Table 5 Comparison of patients enrolled in the
CICD-Pilot registry (2015) and in the EHS (20056)
CICD-Pilot (2015) EHS (2005)
No. of patients 2420 3779
Age (mean+ SD) 66.6+10.9 61+11
% Male 69.5 58
Medical history
Diabetes mellitus (%) 29.2 18
Dyslipidaemia (%) 74.1 58
Hypertension (%) 82.6 62
Previous cerebrovascular
disease (%)
16.4 5
Malignancy (%) 6.6 2
Investigations
Echocardiography (%) 70 64
Ischaemia stress tests (%)a 50 (stable CAD)/
37 (elective PCI)
76/18
Treatment at discharge
ACE-I 65.1 40
Beta-blockers 80.2 67
Statins 92.7 48
Aspirin 90.3 78
Nitrates 11.1 61
Calcium channel blockers 24 27
CICD, chronic ischaemic cardiovascular disease; EHS, Euro Heart Survey; SD,
standard deviation; CAD, coronary artery disease; PCI, percutaneous coronary
intervention; ACE-I, angiotensin-converting enzyme inhibitor; MRI, magnetic
resonance imaging.
aCICD: before/during hospitalization. EHS: during hospitalization/planned. Exercise
test (76)/stress imaging (18).
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Medical history was recorded by investigator’s report as usually
performed in observational studies. However, guidance was pro-
vided in the case report form for important definitions including
hypertension, hyperlipidaemia, or myocardial infarction.
Important heterogeneity also exists between the cohorts due to
different inclusion criteria, but the registry has tried to capture all
aspects of CICD, except STEMI and recent stroke.
Important geographic variations may also exist and reflect differ-
ent levels of availability/affordability of diagnostic procedures and
treatments. The limited size of the current pilot registry makes ana-
lysis of these potential geographic variations difficult and could lead
to erroneous conclusions. It should be better evaluated in the forth-
coming European long-term registry.
As we did not record the dosage of main classes of anti-ischaemic
or preventive medications, we are unable to assess the proportion
of patients at target recommended doses.
Finally, this registry being a pilot phase, only a limited number of
countries are represented. Nevertheless, this registry demonstrated
the feasibility of this data collection on CICD in 10 European coun-
tries and will be followed by a long-term registry, including all volun-
teer members of the ESC with outcome measures.
In summary, the CICD-Pilot registry enrolled patients with the
whole spectrum of ischaemic cardiovascular artery disease, except
for patients with ST elevation ACS.
It shows that European patients with CICD tend to have multiple
comorbidities and that diagnostic procedures recommended by
international guidelines are not put in practice in all patients. There
is, however, a trend for better treatment by antianginal medications
and preventive drugs, compared with previous observations.
Whether this improvement in the management of CICD impacts
favourably on outcomes deserves follow-up studies such as the
forthcoming long-term CICD registry of the ESC.9,10
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